Beigene (NASDAQ:ONC) Price Target Raised to $313.00 at Macquarie

Beigene (NASDAQ:ONC) had its target price increased by Macquarie from $259.00 to $313.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

Beigene Price Performance

Shares of ONC opened at $271.80 on Friday. Beigene has a 52-week low of $126.97 and a 52-week high of $287.88. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $26.60 billion, a price-to-earnings ratio of -32.99, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. As a group, research analysts forecast that Beigene will post -5.82 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Bros. Advisors Lp Baker sold 732,827 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the completion of the sale, the director now owns 730,642 shares in the company, valued at $189,966,920. The trade was a 50.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Xiaobin Wu sold 30,654 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $240.74, for a total value of $7,379,643.96. The disclosure for this sale can be found here. Insiders sold a total of 790,950 shares of company stock worth $204,616,547 over the last quarter. 7.43% of the stock is currently owned by corporate insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.